APOE and Alzheimer disease: Active Aβ immunotherapy agents, such as CAD106, APOE4 homozygotes, APOE4 heterozygotes, umibecestat, anti-Aβ40 antibodies, GV1001 peptide (tertomotide), and UB-311 (synthetic peptide) [14], have been used in the clinical trial stage for AD, most of which have shown low efficacy or side effects.